- Report
- November 2024
- 716 Pages
Global
From €4580EUR$4,799USD£3,837GBP
- Report
- October 2024
- 196 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- February 2025
- 100 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- November 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- April 2023
- 116 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP
The Antibody Drug Conjugates (ADC) Contract Manufacturing market is a subset of the biotechnology industry that focuses on the production of ADCs. ADCs are biopharmaceuticals that combine the targeting ability of monoclonal antibodies with the cytotoxic properties of small molecules. This combination allows for the delivery of a potent drug to a specific target, such as a tumor cell. Contract manufacturing organizations (CMOs) provide the necessary services to develop and manufacture ADCs, including process development, analytical testing, and clinical and commercial manufacturing. CMOs also provide expertise in regulatory affairs, quality assurance, and supply chain management.
Some companies in the ADC Contract Manufacturing market include Lonza, Catalent, and Recipharm. Show Less Read more